Search Result
Results for "
phosphoribosyltransferase
" in MedChemExpress (MCE) Product Catalog:
6
Isotope-Labeled Compounds
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-F0004
-
|
β-Nicotinamide mononucleotide; β-NM; NMN
|
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
|
-
-
- HY-50876
-
Daporinad
Maximum Cited Publications
64 Publications Verification
FK866; APO866
|
NAMPT
Autophagy
Apoptosis
mTOR
p38 MAPK
ERK
|
Cancer
|
|
Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression .
|
-
-
- HY-122502
-
|
Pirazofurin
|
DNA/RNA Synthesis
Antibiotic
Influenza Virus
HIV
SARS-CoV
|
Infection
Cancer
|
|
Pyrazofurin is an antitumor pyrimidine nucleoside analogue and a orotate-phosphoribosyltransferase inhibitor. Pyrazofurin inhibits cell proliferation and intracellular DNA synthesis by inhibiting uridine 5'-phosphate synthase. Pyrazofurin is also an antibiotic with a broad spectrum of antiviral activity .
|
-
-
- HY-147193
-
|
|
NAMPT
|
Cancer
|
|
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC50s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .
|
-
-
- HY-12793
-
|
KPT-9274
|
PAK
NAMPT
|
Cancer
|
|
Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC50s of <100 nM and 120 nM, respectively .
|
-
-
- HY-10079
-
CHS-828
4 Publications Verification
GMX1778
|
NAMPT
Apoptosis
|
Cancer
|
|
CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
|
-
-
- HY-126255
-
|
|
NAMPT
|
Metabolic Disease
|
|
SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD +. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD + in mice .
|
-
-
- HY-W070294
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
8-Azahypoxanthine is a purine analog and an inhibitor of hypoxanthine-guanine phosphoribosyltransferase (HGPRT). 8-Azahypoxanthine exhibits antitumor activity and can be used in the research of tumors such as adenocarcinoma .
|
-
-
- HY-148815
-
|
|
NAMPT
|
Metabolic Disease
|
|
Nampt activator-1 is a nicotinamide phosphoribosyltransferase (NAMPT) activator, with an EC50 of 3.3~3.7 μM. Nampt activator-1 enhances the enzymatic activity of NAMPT. Nampt activator-1 can be used for research related to metabolic disorders .
|
-
-
- HY-F0004S
-
|
β-Nicotinamide mononucleotide-d4; β-NM-d4; NMN-d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
Fosribnicotinamide-d4 (β-Nicotinamide mononucleotide-d4) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
|
-
-
- HY-N8060A
-
|
Orotidine monophosphate trisodium; Orotidylic acid trisodium
|
Endogenous Metabolite
DNA/RNA Synthesis
|
Metabolic Disease
|
|
Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .
|
-
-
- HY-14373
-
|
ZM 242421
|
NAMPT
|
Cancer
|
|
CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC50 values in the 1-10 nM range) . CB30865 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-119413
-
|
|
Adenosine Receptor
|
Neurological Disease
|
|
9-Ethyladenine is a precursor of competitive antagonists of adenosine receptors (A1, A2, A3), with no significant inhibitory effect on adenine phosphoribosyltransferase (APRT). 9-Ethyladenine derivatives have high affinity and selectivity for A1 (Ki=27 nM), A2A (Ki=46 nM), and A3 (Ki=86 nM) receptors. 9-Ethyladenine does not inhibit brain APRT activity, can be used in the study of adenosine receptor-related diseases (such as nervous system diseases) models .
|
-
-
- HY-W013111
-
|
dGDP trisodium; 2'-Deoxyguanosine-5'-diphosphate trisodium
|
Nucleoside Antimetabolite/Analog
Parasite
|
Infection
|
|
2′-Deoxy-GDP (dGDP) trisodium, a guanosine monophosphate (GMP) analogue, is a hypoxanthine phosphoribosyltransferase (HGPRT) inhibitor with an IC50 of 12.5 μM. HGPRT is a central enzyme in the purine recycling pathway of all protozoan parasites .
|
-
-
- HY-N9941
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
2,8-Dihydroxyadenine, an endogenous metabolite, can cause the formation of urinary crystals and kidney stones. 2,8-Dihydroxyadenine can be used to diagnose adenine phosphoribosyltransferase (APRT) deficiency .
|
-
-
- HY-108701
-
|
|
NAMPT
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death .
|
-
-
- HY-F0004R
-
|
β-Nicotinamide mononucleotide (Standard); β-NM (Standard); NMN (Standard)
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard)) is the analytical standard of Fosribnicotinamide (HY-F0004
). This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
|
-
-
- HY-163499
-
|
|
NAMPT
|
Cancer
|
|
NAMPT activator-7 (Compound 232) is an activator for nicotinamide phosphoribosyltransferase (NAMPT), with EC50 < 0.5 μM. NAMPT activator-7 activates NAMPT in cells U2OS with cellular EC50 of < 0.5 μM .
|
-
-
- HY-163500
-
|
|
NAMPT
|
Cancer
|
|
NAMPT activator-8 (Compound 278) is an activator for nicotinamide phosphoribosyltransferase (NAMPT), with EC50 < 0.5 μM. NAMPT activator-8 activates NAMPT in cells U2OS with cellular EC50 of < 0.5 μM .
|
-
-
- HY-147193A
-
|
|
NAMPT
|
Cancer
|
|
Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC50 values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .
|
-
-
- HY-163280
-
|
|
NAMPT
|
Neurological Disease
|
|
JGB-1-155 is a positive allosteric modulators (N-PAMs), which enhances the activity of nicotinamide phosphoribosyltransferase NAMPT with EC50 of 3.29 μM. JGB-1-155 counteracts the oxidative stress, through upregulating the NAD + in THP-1 human monocytes. JGB-1-155 attenuates TNFα-induced ROS in HT-22 cells .
|
-
-
- HY-W1117786
-
|
|
ADC Payload
NAMPT
|
Cancer
|
|
Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity .
|
-
-
- HY-158323
-
|
|
Parasite
|
Infection
Cancer
|
|
HGPRT/TBrHGPRT1-IN-1 (Compound 5) is a selective inhibitor targeting human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Trypanosoma bruce HGPRT1 (TBrHGPRT1) (both Ki=3 nM). HGPRT/TBrHGPRT1-IN-1 ultimately results in decreased cell growth. HGPRT/TBrHGPRT1-IN-1 is primarily used in the research of infectious diseases and cancer .
|
-
-
- HY-N5134S5
-
|
5'-GMP-13C10,15N5 dilithium; 5'-guanosine monophosphate-13C10,15N5 dilithium
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
5'-Guanylic acid- 13C10, 15N5 (5'-GMP- 13C10, 15N5 dilithium; 5'-guanosine monophosphate- 13C10, 15N5) dilithium is 13C and 15N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-W587952
-
|
|
NAMPT
|
Others
|
|
Gibberellin A34 is a Hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1) inhibitor that can be isolated from immature seeds of Calonyction aculeatum. Gibberellin A34 can be used for studies on plant growth and development regulation .
|
-
-
- HY-144294
-
|
|
Parasite
|
Infection
|
|
Purine phosphoribosyltransferase-IN-1 (Compound (S,R)-48) is a potent inhibitor of the Plasmodium falciparum (Pf), P. vivax (Pv) and Trypanosoma brucei (Tbr) 6-oxopurine purine phosphoribosyltransferases (PRTs), with Ki values of 50, 20, and 2 nM, respectively .
|
-
-
- HY-144296
-
|
|
Parasite
|
Infection
|
|
Purine phosphoribosyltransferase-IN-2 is a potent inhibitor of the Plasmodium falciparum ((Pf)), Plasmodium vivax ((Pv)) and Trypanosoma brucei ((Tbr)) 6-oxopurine phosphoribosyltransferase (PRT), with Kis of 30, 20 and 2 nM, respectively .
|
-
-
- HY-130606
-
|
|
NAMPT
Cytochrome P450
|
Cancer
|
|
Nampt-IN-5 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-5 also inhibits CYP3A4 activity and has cellular IC50s of 0.7 nM and 3.9 nM against A2780 and COR-L23, respectively .
|
-
-
- HY-147656
-
|
|
ATTECs
NAMPT
Autophagy
|
Cancer
|
|
NAMPT degrader-1 (Compound A3), an autophagosome-tethering compound (ATTEC), is an nicotinamide phosphoribosyltransferase (NAMPT) degrader with an IC50 of 0.023 μM. NAMPT degrader-1 significantly induces the degradation of NAMPT through the autophagy-lysosomal pathway and shows excellent cellular antitumor potency .
|
-
-
- HY-159009
-
|
|
NAMPT
Ligands for Target Protein for PROTAC
|
Cancer
|
|
MS7 is a potent inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is overexpressed in many cancer cells to meet the continuous replenishment of NAD + required for rapid proliferation. MS7, as a NAMPT target protein ligand, can be used to synthesize PROTAC A7, which is an effective NAMPT degrader. MS7 can be used in cancer research .
|
-
-
- HY-W010354
-
|
|
Drug Intermediate
|
Infection
|
|
2,2-Diethoxyethanol is a drug intermediate used in research related to Plasmodium falciparum infection .
|
-
-
- HY-175294
-
|
|
PD-1/PD-L1
NAMPT
|
Cancer
|
|
PD-L1/Nampt-IN-1 is an orally active inhibitor that simultaneously target PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50s value of 63 nM and 582 nM. PD-L1/Nampt-IN-1 demonstrates cross-species affinity with comparable KD values for hPD-L1 (52.6 nM) and mPD-L1 (49.1 nM), respectively. PD-L1/Nampt-IN-1 effectively inhibits tumor growth by activating the tumor immune microenvironment. PD-L1/Nampt-IN-1 can be used for the study of melanoma .
|
-
-
- HY-101280A
-
|
|
NAMPT
|
Cancer
|
|
LB-60-OF61 hydrochloride is a potent NAMPT (nicotinamide phosphoribosyltransferase) inhibitor. LB-60-OF61 hydrochloride is a cytotoxic compound with a selectivity towards MYC overexpressing cell lines .
|
-
-
- HY-159016
-
|
|
PROTACs
|
Cancer
|
|
SIAIS630121-NC (compound 630121-NC) is a negative control for NAMPT (nicotinamide phosphoribosyltransferase) PROTAC degrader SIAIS630121. SIAIS630121-NC shows no NAMPT degradation capability at all .
|
-
-
- HY-10079A
-
|
GMX1778 (nicotinate)
|
NAMPT
Apoptosis
|
Cancer
|
|
CHS-828 nicotinate is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 nicotinate (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
|
-
-
- HY-159015
-
|
|
PROTACs
|
Cancer
|
|
SIAIS630120-NC is a negative control for NAMPT (nicotinamide phosphoribosyltransferase) degrader SIAIS630120 (Sturcture Note:(Blue: Cereblon ligand Thalidomide (HY-14658) analogue (HY-138793), Black: linker;Pink: Nampt inhibitor FK866 (HY-50876)) .
|
-
-
- HY-10079R
-
|
GMX1778 (Standard)
|
Reference Standards
NAMPT
Apoptosis
|
Cancer
|
|
CHS-828 (Standard) is the analytical standard of CHS-828. This product is intended for research and analytical applications. CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity .
|
-
-
- HY-N5134S2
-
|
5'-GMP-15N5 dilithium; 5'-guanosine monophosphate-15N5 dilithium
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
5'-Guanylic acid- 15N5 (5'-GMP- 15N5 dilithium; 5'-guanosine monophosphate- 15N5) dilithium is 15N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-N5134S1
-
|
5'-GMP-13C10 dilithium; 5'-guanosine monophosphate-13C10 dilithium
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
5'-Guanylic acid- 13C10 (5'-GMP- 13C10 dilithium; 5'-guanosine monophosphate- 13C10) dilithium is 13C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-N5134S3
-
|
5'-GMP-d12 dilithium; 5'-guanosine monophosphate-d12 dilithium
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
5'-Guanylic acid-d12 (5'-GMP-d12 dilithium; 5'-guanosine monophosphate-d12) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-158319
-
|
|
Apoptosis
Isocitrate Dehydrogenase (IDH)
NAMPT
|
Cancer
|
|
Mutant IDH1/NAMPT-IN-1 (Compound 23h) is a dual inhibitor of mutant isocitrate dehydrogenase 1 (mutant IDH1) (IC50=14.93 nM) and nicotinamide phosphoribosyltransferase (NAMPT) (IC50=12.56 nM). Mutant IDH1/NAMPT-IN-1 can induce apoptosis. Mutant IDH1/NAMPT-IN-1 crosses the blood-brain barrier effectively .
|
-
-
- HY-N5134S4
-
|
5'-GMP-15N5,d12 dilithium; 5'-guanosine monophosphate-15N5,d12 dilithium
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
5'-Guanylic acid- 15N5,d12 (5'-GMP- 15N5,d12 dilithium; 5'-guanosine monophosphate- 15N5,d12) dilithium is deuterium and 15N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-181880
-
|
|
PROTACs
NAMPT
|
Cancer
|
|
PROTAC NAMPT Degrader-28 is a NAMPT PROTAC degrader with DC50 values of 45 nM and 55 nM in MCF7 and 4T1cl5 cells, respectively. PROTAC NAMPT Degrader-28 retains nicotinamide phosphoribosyltransferase inhibitory activity and does not induce degradation of this enzyme. PROTAC NAMPT Degrader-28 can be used in breast cancer-related research .
|
-
-
- HY-182567
-
|
|
NAMPT
|
Cancer
|
|
Nampt-IN-19 is an orally active and non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a human Ki of 5.6 nM. Nampt-IN-19 blocks NAD + biosynthesis from Nicotinamide (HY-B0150). Nampt-IN-19 acts as an antiproliferative agent in cancer cells. Nampt-IN-19 has preclinical pharmacokinetic properties supporting oral antitumor activity in mouse xenograft models. Nampt-IN-19 can be used for the research of colorectal cancer .
|
-
-
- HY-186105
-
|
|
NAMPT
|
Neurological Disease
|
|
P7C3-S243 is a brain-penetrant P7C3 class of neuroprotective agent. P7C3-S243 augments synthesis of nicotinamide adenine dinucleotide through activation of the metabolic enzyme nicotinamide phosphoribosyltransferase. P7C3-S243 shows potent neuroprotective efficacy in parkinson’s disease mice models. P7C3-S243 can be used for the research of parkinson’s disease .
|
-
-
- HY-181350
-
|
|
Carbonic Anhydrase
NAMPT
Apoptosis
Reactive Oxygen Species (ROS)
ERK
Akt
DNA/RNA Synthesis
Mitochondrial Metabolism
|
Cancer
|
|
CAIX/XII/NAMPT-IN-1 is a triple inhibitor of carbonic anhydrase IX/XII and nicotinamide phosphoribosyltransferase (NAMPT) with a hCA IX Ki of 78.1 nM, hCA XII Ki of 64.4 nM, and hNAMPT IC50 of 168 nM. CAIX/XII/NAMPT-IN-1 induces apoptosis, ROS accumulation, suppresses ERK/AKT signaling, inhibits DNA synthesis, and causes mitochondrial dysfunction. CAIX/XII/NAMPT-IN-1 exerts antiproliferative effects against multiple cancer cells under normoxic and hypoxic conditions. CAIX/XII/NAMPT-IN-1 can be used for the research of cancer, such as renal carcinoma, glioblastoma and colorectal cancer .
|
-
-
- HY-181882
-
-
-
- HY-108701R
-
|
|
Reference Standards
NAMPT
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Nampt-IN-3 (Standard) is the analytical standard of Nampt-IN-3 (HY-108701). This product is intended for research and analytical applications. Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death .
|
-
-
- HY-179523
-
|
|
Drug Derivative
NAMPT
Microtubule/Tubulin
|
Neurological Disease
Cancer
|
|
Carba1 is a bifunctional Carbazole (HY-D0204) derivative that activates nicotinamide phosphoribosyltransferase (NAMPT) and enhances NAD biosynthesis. Carba1 binds to colchicine site of tubulin, enhancing the anti-tumor effect of various chemotherapy drugs, such as Paclitaxel (HY-B0015). Carba1 exerts neuroprotective effect and can regulate cell energy metabolism. Carba1 can be used for the researches of cancer and chemotherapy-induced peripheral neuropathy (CIPN) .
|
-
-
- HY-50876A
-
|
FK866 hydrochloride; APO866 hydrochloride
|
NAMPT
Autophagy
Apoptosis
mTOR
p38 MAPK
ERK
|
Inflammation/Immunology
Cancer
|
|
Daporinad (FK866) hydrochloride is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad hydrochloride depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad hydrochloride causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad hydrochloride induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad hydrochloride can be used for the study of myeloma, liver cancer, and immunosuppression .
|
-
| Cat. No. |
상품명 |
Category |
Target |
Chemical Structure |
| Cat. No. |
상품명 |
Chemical Structure |
-
- HY-F0004S
-
|
|
|
Fosribnicotinamide-d4 (β-Nicotinamide mononucleotide-d4) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
|
-
-
- HY-N5134S5
-
|
|
|
5'-Guanylic acid- 13C10, 15N5 (5'-GMP- 13C10, 15N5 dilithium; 5'-guanosine monophosphate- 13C10, 15N5) dilithium is 13C and 15N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-N5134S2
-
|
|
|
5'-Guanylic acid- 15N5 (5'-GMP- 15N5 dilithium; 5'-guanosine monophosphate- 15N5) dilithium is 15N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-N5134S1
-
|
|
|
5'-Guanylic acid- 13C10 (5'-GMP- 13C10 dilithium; 5'-guanosine monophosphate- 13C10) dilithium is 13C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-N5134S3
-
|
|
|
5'-Guanylic acid-d12 (5'-GMP-d12 dilithium; 5'-guanosine monophosphate-d12) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
-
- HY-N5134S4
-
|
|
|
5'-Guanylic acid- 15N5,d12 (5'-GMP- 15N5,d12 dilithium; 5'-guanosine monophosphate- 15N5,d12) dilithium is deuterium and 15N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
| Cat. No. |
상품명 |
|
Classification |
-
- HY-14373
-
|
ZM 242421
|
|
Alkynes
|
|
CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC50 values in the 1-10 nM range) . CB30865 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- 상품명:
- Cat. No.:
- 수량:
- MCE Japan Authorized Agent: